FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202635005> ?p ?o ?g. }

• W3202635005 endingPage "99.e7" @default.
• W3202635005 startingPage "99.e1" @default.
• W3202635005 abstract "Treosulfan-based conditioning has gained popularity in pediatric allogeneic hematopoietic stem cell transplantation (HSCT) because of its presumed favorable efficacy and toxicity profile. Treosulfan is used in standardized dosing regimens based on body surface area. The relationships between systemic treosulfan exposure and early and long-term clinical outcomes in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases remain unclear. In this a multicenter, prospective observational study, we assessed the association between treosulfan exposure and early and, in particular, long-term clinical outcomes. Our study cohort comprised 110 pediatric patients with nonmalignant diseases who underwent HSCT between 2011 and 2019 in Leiden, The Netherlands and Rome, Italy. Blood samples were collected, and treosulfan area under the receiver operating characteristic curve (AUC0-∞) was estimated as a measure of exposure. Cox proportional hazard survival analyses were performed to assess the relationships between treosulfan exposure and overall survival (OS) and event-free survival (EFS). The predictive value of systemic treosulfan exposure for the occurrence of toxicity within 28 days was evaluated using a multivariable logistic regression analysis. In the overall cohort, OS and EFS at 2 years were 89.0% and 75.3%, respectively, with an excellent OS of 97% in children age <2 years. The occurrence of grade II-IV acute graft-versus-host disease, the level of 1-year whole blood chimerism, and 2-year OS and EFS were not correlated with treosulfan exposure. The occurrence of skin toxicity (odds ratio [OR], 3.97; 95% confidence interval [CI], 1.26-13.68; P = .02) and all-grade mucositis (OR, 4.43; 95% CI, 1.43-15.50; P = .02), but not grade ≥2 mucositis (OR, 1.51; 95% CI, 0.52 to 4.58; P = .46) was related to high treosulfan exposure (>1750 mg*h/L). Our study demonstrates that standardized treosulfan-based conditioning results in a favorable OS and EFS in infants and children with nonmalignant diseases, independent of interindividual variation in treosulfan exposure. These outcomes can be achieved without the need for therapeutic drug monitoring, thereby emphasizing the advantage of treosulfan use in this category of patients. Although higher treosulfan exposure increases the risk of skin toxicity, there is no absolute necessity for therapeutic drug monitoring if proper preventive skin measures are taken. More research is needed to assess whether deescalation of treosulfan doses is possible to minimize early and long-term toxicity without compromising efficacy." @default.
• W3202635005 created "2021-10-11" @default.
• W3202635005 creator A5000530040 @default.
• W3202635005 creator A5002439246 @default.
• W3202635005 creator A5006908595 @default.
• W3202635005 creator A5017556252 @default.
• W3202635005 creator A5022712318 @default.
• W3202635005 creator A5026927916 @default.
• W3202635005 creator A5044310123 @default.
• W3202635005 creator A5044983081 @default.
• W3202635005 creator A5053532854 @default.
• W3202635005 creator A5058166328 @default.
• W3202635005 creator A5069107002 @default.
• W3202635005 creator A5076321542 @default.
• W3202635005 creator A5077335202 @default.
• W3202635005 date "2022-02-01" @default.
• W3202635005 modified "2023-09-27" @default.
• W3202635005 title "Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study" @default.
• W3202635005 cites W1194989569 @default.
• W3202635005 cites W1954992673 @default.
• W3202635005 cites W1987208035 @default.
• W3202635005 cites W2008973770 @default.
• W3202635005 cites W2012434943 @default.
• W3202635005 cites W2014898379 @default.
• W3202635005 cites W2045682738 @default.
• W3202635005 cites W2051443179 @default.
• W3202635005 cites W2086024031 @default.
• W3202635005 cites W2152930906 @default.
• W3202635005 cites W2153229010 @default.
• W3202635005 cites W2328093288 @default.
• W3202635005 cites W2334769895 @default.
• W3202635005 cites W2403934281 @default.
• W3202635005 cites W2530375062 @default.
• W3202635005 cites W2595371676 @default.
• W3202635005 cites W2602273320 @default.
• W3202635005 cites W2731180117 @default.
• W3202635005 cites W2761170574 @default.
• W3202635005 cites W2766709436 @default.
• W3202635005 cites W2771824299 @default.
• W3202635005 cites W2892057079 @default.
• W3202635005 cites W2947109453 @default.
• W3202635005 cites W2947567067 @default.
• W3202635005 cites W2986767939 @default.
• W3202635005 cites W3012093235 @default.
• W3202635005 doi "https://doi.org/10.1016/j.jtct.2021.09.018" @default.
• W3202635005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34607071" @default.
• W3202635005 hasPublicationYear "2022" @default.
• W3202635005 type Work @default.
• W3202635005 sameAs 3202635005 @default.
• W3202635005 citedByCount "11" @default.
• W3202635005 countsByYear W32026350052022 @default.
• W3202635005 countsByYear W32026350052023 @default.
• W3202635005 crossrefType "journal-article" @default.
• W3202635005 hasAuthorship W3202635005A5000530040 @default.
• W3202635005 hasAuthorship W3202635005A5002439246 @default.
• W3202635005 hasAuthorship W3202635005A5006908595 @default.
• W3202635005 hasAuthorship W3202635005A5017556252 @default.
• W3202635005 hasAuthorship W3202635005A5022712318 @default.
• W3202635005 hasAuthorship W3202635005A5026927916 @default.
• W3202635005 hasAuthorship W3202635005A5044310123 @default.
• W3202635005 hasAuthorship W3202635005A5044983081 @default.
• W3202635005 hasAuthorship W3202635005A5053532854 @default.
• W3202635005 hasAuthorship W3202635005A5058166328 @default.
• W3202635005 hasAuthorship W3202635005A5069107002 @default.
• W3202635005 hasAuthorship W3202635005A5076321542 @default.
• W3202635005 hasAuthorship W3202635005A5077335202 @default.
• W3202635005 hasBestOaLocation W32026350051 @default.
• W3202635005 hasConcept C126322002 @default.
• W3202635005 hasConcept C141071460 @default.
• W3202635005 hasConcept C188816634 @default.
• W3202635005 hasConcept C207103383 @default.
• W3202635005 hasConcept C2777408962 @default.
• W3202635005 hasConcept C2779178397 @default.
• W3202635005 hasConcept C2780611847 @default.
• W3202635005 hasConcept C2911091166 @default.
• W3202635005 hasConcept C44249647 @default.
• W3202635005 hasConcept C50382708 @default.
• W3202635005 hasConcept C71924100 @default.
• W3202635005 hasConcept C72563966 @default.
• W3202635005 hasConceptScore W3202635005C126322002 @default.
• W3202635005 hasConceptScore W3202635005C141071460 @default.
• W3202635005 hasConceptScore W3202635005C188816634 @default.
• W3202635005 hasConceptScore W3202635005C207103383 @default.
• W3202635005 hasConceptScore W3202635005C2777408962 @default.
• W3202635005 hasConceptScore W3202635005C2779178397 @default.
• W3202635005 hasConceptScore W3202635005C2780611847 @default.
• W3202635005 hasConceptScore W3202635005C2911091166 @default.
• W3202635005 hasConceptScore W3202635005C44249647 @default.
• W3202635005 hasConceptScore W3202635005C50382708 @default.
• W3202635005 hasConceptScore W3202635005C71924100 @default.
• W3202635005 hasConceptScore W3202635005C72563966 @default.
• W3202635005 hasIssue "2" @default.
• W3202635005 hasLocation W32026350051 @default.
• W3202635005 hasLocation W32026350052 @default.
• W3202635005 hasLocation W32026350053 @default.
• W3202635005 hasOpenAccess W3202635005 @default.
• W3202635005 hasPrimaryLocation W32026350051 @default.
• W3202635005 hasRelatedWork W1727188710 @default.

• next